Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PONENTE benralizumab oral corticosteroid reduction study in severe eosinophilic asthma
2018-000170-30Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Primary endpoint: Sustained complete oral corticosteroid reduction. Started Jun 2018; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2018-000170-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000170-30.